Handicappers Debate Chances Of Genentech’s Avastin In Breast Cancer
As clock ticks down to tomorrow’s user fee date for Avastin, “ambivalent and ambiguous” agency hard to outguess, analyst tells “The Pink Sheet” DAILY.
As clock ticks down to tomorrow’s user fee date for Avastin, “ambivalent and ambiguous” agency hard to outguess, analyst tells “The Pink Sheet” DAILY.